Literature DB >> 15357315

The genetic immunodeficiency disease, leukocyte adhesion deficiency, in humans, dogs, cattle, and mice.

Yu-Chen Gu1, Thomas R Bauer, Mark R Ackermann, C Wayne Smith, Marcus E Kehrli, Matthew F Starost, Dennis D Hickstein.   

Abstract

This review highlights the genotype-phenotype relationship of the genetic immunodeficiency disease leukocyte adhesion deficiency (LAD) in humans, dogs, cattle, and mice, and provides assessment of the opportunities that each animal species provides in the understanding of leukocyte biology and in developing new therapeutic approaches to LAD in humans. This comparison is important since animal models of genetic diseases in humans provide the opportunity to test new therapeutic approaches in an appropriate, disease-specific model. The success of this approach is dependent on the relationship of the phenotype in the animal to the phenotype of the disease in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357315

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  7 in total

1.  Leukocyte integrin activation mediates transient neutropenia after G-CSF administration.

Authors:  Robert E Donahue; Laura Tuschong; Thomas R Bauer; Yu Ying Yau; Susan F Leitman; Dennis D Hickstein
Journal:  Blood       Date:  2011-08-15       Impact factor: 22.113

2.  Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.

Authors:  T R Bauer; E M Olson; Y Huo; L M Tuschong; J M Allen; Y Li; T H Burkholder; D W Russell
Journal:  Gene Ther       Date:  2011-01-13       Impact factor: 5.250

3.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

4.  Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response.

Authors:  Anna I Markowska; Fu-Tong Liu; Noorjahan Panjwani
Journal:  J Exp Med       Date:  2010-08-16       Impact factor: 14.307

5.  Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Authors:  Arta M Monjazeb; Michael S Kent; Steven K Grossenbacher; Christine Mall; Anthony E Zamora; Annie Mirsoian; Mingyi Chen; Amir Kol; Stephen L Shiao; Abhinav Reddy; Julian R Perks; William T N Culp; Ellen E Sparger; Robert J Canter; Gail D Sckisel; William J Murphy
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

6.  Inhibitors of selectin functions in the treatment of inflammatory skin disorders.

Authors:  Michael P Schön
Journal:  Ther Clin Risk Manag       Date:  2005-09       Impact factor: 2.423

Review 7.  Impact of gene therapy for canine monogenic diseases on the progress of preclinical studies.

Authors:  Marek Switonski
Journal:  J Appl Genet       Date:  2020-03-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.